Loading insider details...
Beta
Latest Form 4 (Jul 7, 2026): Exercise/Conversion of 6,000 GLUE shares, $36.8K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 7, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Exercise/Conversion | 6,000 | $36.8K |
| Jun 25, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Exercise/Conversion | 3,000 | $18.4K |
| Jun 18, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Exercise/Conversion | 3,000 | $18.4K |
| Jun 1, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Exercise/Conversion | 6,000 | $36.8K |
| Jan 5, 2026 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 35,000 | n/a |
| Jan 6, 2025 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 36,000 | n/a |
| Jun 5, 2024 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 40,000 | n/a |
| Jan 4, 2023 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 78,550 | n/a |
| Mar 2, 2022 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/Award | 70,000 | n/a |